Substance / Medication

Dibasic potassium phosphate

Overview

Active Ingredient
dibasic potassium phosphate
RxNorm CUI
55018

Indications

Potassium Phosphates Injection is indicated as a source of phosphorus: • in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. • for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated.

Labeler: Hospira, Inc.Updated: 2025-09-30T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Potassium Phosphates Injection is contraindicated in patients with: • Warning and Precautions (5.3) [see] hyperkalemia • 2 Warning and Precautions (5.3) [see] severe renal impairment (eGFR less than 30 mL/min/1.73m) or end stage renal disease • Warning and Precautions (5.4) [see] hyperphosphatemia •

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Ferric Carboxymaltose (FCM)-Associated Hypophosphatemia (HPP): A Systematic Review.
Magagnoli Joseph, Knopf Kevin, Hrushesky William J et al. · Am J Hematol · 2025
PMID: 39935027Meta-AnalysisFull text (PMC)
Intracranial phosphaturic mesenchymal tumor: A rare case report and systematic review.
Song Shuyue, Zhao Yuyang, Wang Yiquan et al. · Medicine (Baltimore) · 2025
PMID: 39993076Meta-AnalysisFull text (PMC)
Non-Severe Hypophosphatemia in Older Patients: A Systematic Review.
Barbarossa Luca, Zandonà Martina, Garo Maria Luisa et al. · Nutrients · 2025
PMID: 40284219Meta-AnalysisFull text (PMC)
Indications for the evaluation and supplementation of hypophosphatemia: an umbrella systematic review of reviews and guidelines.
Netzer Seraina, Büchel Lea, Büchi Annina E et al. · BMC Med · 2025
PMID: 41146174Meta-AnalysisFull text (PMC)
Hereditary Hypophosphatemic Rickets with Hypercalciuria Presenting with Enthesopathy, Renal Cysts, and High Serum c-Terminal FGF23: Single-Center Experience and Systematic Review.
Dodamani Manjunath Havalappa, Memon Saba Samad, Karlekar Manjiri et al. · Calcif Tissue Int · 2024
PMID: 37981601Meta-Analysis
Postoperative Hypophosphatemia as a Prognostic Factor for Postoperative Pancreatic Fistula: A Systematic Review.
Grikyte Ieva, Ignatavicius Povilas · Medicina (Kaunas) · 2023
PMID: 36837475Meta-AnalysisFull text (PMC)
Tumor-Induced Osteomalacia in Patients With Malignancy: A Meta-analysis and Systematic Review of Case Reports.
Bouraima Farouk, Sapin Vincent, Kahouadji Samy et al. · J Clin Endocrinol Metab · 2023
PMID: 37235783Meta-Analysis
Efficacy and Safety of Burosumab in X-linked Hypophosphatemia.
Wang Sen, Wang Xiaoqin, He Miao et al. · J Clin Endocrinol Metab · 2023
PMID: 37497620Meta-Analysis
S-1 and 5-Fluorouracil-related adverse events in patients with advanced gastric cancer: A meta-analysis.
Hu Qingqing, Xu Jiajia, Ke Jingshu et al. · PLoS One · 2023
PMID: 37566608Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dibasic potassium phosphate (substance)
SNOMED CT
73722009
UMLS CUI
C0138037
RxNorm CUI
55018
Labeler
Hospira, Inc.

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.